US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Psoriasis Drugs market. Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Psoriasis Drugs market." Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin. These skin patches are typically red, itchy, and scaly. Psoriasis varies in severity from small, localized patches to complete body coverage. The global Psoriasis Drugs market is valued at 12600 million US$ in 2018 is expected to reach 25600 million US$ by the end of 2025, growing at a CAGR of 9.3% during 2019-2025. This report focuses on Psoriasis Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Psoriasis Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report. The following manufacturers are covered: AbbVie Amgen Johnson & Johnson Novartis Eli Lilly AstraZeneca Celgene ... Segment by Regions North America Europe China Japan Segment by Type TNF-inhibitors Interleukin-inhibitors Others Segment by Application Hospital Clinic
Table of Contents Executive Summary 1 Psoriasis Drugs Market Overview 1.1 Product Overview and Scope of Psoriasis Drugs 1.2 Psoriasis Drugs Segment by Type 1.2.1 Global Psoriasis Drugs Production Growth Rate Comparison by Type (2014-2025) 1.2.2 TNF-inhibitors 1.2.3 Interleukin-inhibitors 1.2.4 Others 1.3 Psoriasis Drugs Segment by Application 1.3.1 Psoriasis Drugs Consumption Comparison by Application (2014-2025) 1.3.2 Hospital 1.3.3 Clinic 1.4 Global Psoriasis Drugs Market by Region 1.4.1 Global Psoriasis Drugs Market Size Region 1.4.2 North America Status and Prospect (2014-2025) 1.4.3 Europe Status and Prospect (2014-2025) 1.4.4 China Status and Prospect (2014-2025) 1.4.5 Japan Status and Prospect (2014-2025) 1.5 Global Psoriasis Drugs Market Size 1.5.1 Global Psoriasis Drugs Revenue (2014-2025) 1.5.2 Global Psoriasis Drugs Production (2014-2025) 2 Global Psoriasis Drugs Market Competition by Manufacturers 2.1 Global Psoriasis Drugs Production Market Share by Manufacturers (2014-2019) 2.2 Global Psoriasis Drugs Revenue Share by Manufacturers (2014-2019) 2.3 Global Psoriasis Drugs Average Price by Manufacturers (2014-2019) 2.4 Manufacturers Psoriasis Drugs Production Sites, Area Served, Product Types 2.5 Psoriasis Drugs Market Competitive Situation and Trends 2.5.1 Psoriasis Drugs Market Concentration Rate 2.5.2 Psoriasis Drugs Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion 3 Global Psoriasis Drugs Production Market Share by Regions 3.1 Global Psoriasis Drugs Production Market Share by Regions 3.2 Global Psoriasis Drugs Revenue Market Share by Regions (2014-2019) 3.3 Global Psoriasis Drugs Production, Revenue, Price and Gross Margin (2014-2019) 3.4 North America Psoriasis Drugs Production 3.4.1 North America Psoriasis Drugs Production Growth Rate (2014-2019) 3.4.2 North America Psoriasis Drugs Production, Revenue, Price and Gross Margin (2014-2019) 3.5 Europe Psoriasis Drugs Production 3.5.1 Europe Psoriasis Drugs Production ... | read more...